A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.

Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...

The UK DRI has announced an international research study to assess whether a finger-prick blood test could help diagnose ...

Lipocine has completed the enrolment and participant dosing in its Phase III clinical trial investigating LPCN 1154 to treat ...

Tanabe Pharma America, a subsidiary of the Tanabe Pharma Corporation, is not the only company developing drugs for EPP and ...

Adalyon’s CEO, Ulrik Zeuthen, notes that speech-based biomarkers can be used across several applications to optimise trial ...

Genespire is looking to take its single-dose gene therapy, GENE202, to the clinic by the end of 2026, where it will be ...

Genmab has announced topline results from the Phase III EPCORE DLBCL-1 trial, highlighting improved PFS for its subcutaneous ...

BBH has entered a partnership with PhaseWell Research aimed at expanding access to neuropsychiatric clinical trials.

Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap its development.

William Blair analysts view Elevidys’ three-year outcome as a win for Sarepta, though they remain sceptical on the readout’s sales impact.

Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule GLP-1 receptor agonist, intended for treating type 2 diabetes mellitus.